DAEHAN NEW PHARM CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,950 KRW | +0.13% |
|
+0.38% | -12.15% |
| Sales 2009 | 40.4B 29.37M 2.35B | Sales 2010 | 49.65B 36.09M 2.89B | Capitalization | 112B 81.77M 6.55B |
|---|---|---|---|---|---|
| Net income 2009 | 361M 262K 21.01M | Net income 2010 | -2.77B -2.01M -161M | EV / Sales 2009 | 3.65 x |
| Net Debt 2009 | 23.74B 17.26M 1.38B | Net Debt 2010 | 34.86B 25.34M 2.03B | EV / Sales 2010 | 2.97 x |
| P/E ratio 2009 |
347
x | P/E ratio 2010 |
-41.6
x | Employees | 228 |
| Yield 2009 * |
-
| Yield 2010 |
-
| Free-Float | 57.68% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.13% | ||
| 1 week | +0.38% | ||
| Current month | -4.45% | ||
| 1 month | -5.69% | ||
| 3 months | -8.62% | ||
| 6 months | -3.17% | ||
| Current year | -12.15% |
1 week
7 670.00
7 990.00
1 month
7 670.008 380.00
Current year
7 670.009 300.00
1 year
7 670.0010 410.00
3 years
7 670.0014 400.00
5 years
5 230.0015 950.00
10 years
5 230.0042 100.00
| Managers | Title | Age | Since |
|---|---|---|---|
Wan-Jin Lee
CEO | Chief Executive Officer | 72 | - |
Jang-Su Choi
DFI | Director of Finance/CFO | 57 | - |
Won-Seok Lee
BRD | Director/Board Member | 46 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wan-Jin Lee
CEO | Chief Executive Officer | 72 | - |
Won-Seok Lee
BRD | Director/Board Member | 46 | - |
Oh-Gyeong Kwon
BRD | Director/Board Member | 70 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 7,950 | +0.13% | 12,440 |
| 25/04/24 | 7,940 | +0.76% | 10,570 |
| 24/04/24 | 7,880 | +2.07% | 22,262 |
| 23/04/24 | 7,720 | -2.40% | 72,861 |
| 22/04/24 | 7,910 | -0.13% | 127,425 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Daehan New Pharm Co., Ltd. is a Korea-based company specialized in the provision of pharmaceutical products. The Company provides two categories of products: human pharmaceutical products and animal pharmaceutical products. Its human pharmaceutical products include analgesics, anti-inflammatory drugs, antipyretics, antibacterial, antidiabetics, antihistamines, antineoplastics, immunosuppressants, cardiovascular drugs, gastrointestinal drugs, muscle relaxants, antispasmodics and others. Its animal pharmaceutical products include antibacterial, coccidiostats, antihelmintics, probiotic, nutrients, metabolic stimulants, disinfectants, functional supplement feeds, liver tonics, antihelmintics and others for poultries, cattle, sheep, swine and fishes.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.15% | 81.07M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- A054670 Stock
